ARK Stock Commentary: NU, PRME, PACB, SDGR, BEAM, RBLX, CDNA, ILMN, QSI, BLSH
Why this is in the vault
Weekly roundup of ARK's own ≥15%-in-a-day movers, filed mainly to extend the running QSI "no-news" pattern log and to note PACB's rare real catalyst (a US import ban on a Chinese sequencing maker) against three prior PACB/QSI entries that had no company-specific news at all.
⚠️ Sponsorship
ARK Invest is an active fund manager writing about stocks it holds in its own strategies (per the email's own framing: "stocks in our strategies that have appreciated or dropped more than 15% in a day"). All ten names in this issue are ARK portfolio holdings; the commentary describes price moves and business lines without disclosing ARK's position size, cost basis, or whether ARK traded around any of these moves. sponsored: true / sponsor_entity: self per the established ARK Invest pattern in this vault.
Curation section
- NU Holdings (NU), -19% Mon — Dropped after Brazil President Lula's unexpected re-election rattled markets and forced a reassessment of Brazil's fiscal/currency/rate path. NU is a Latin American digital bank.
- Prime Medicine (PRME), +20% Tue / +23% Wed — Rose after the FDA issued draft guidance letting a single Biologics License Application cover multiple variant-specific gene editors, relevant to PRME's two-variant Wilson-disease (PM577) program. Prime Medicine develops curative prime-editing therapies for rare diseases.
- Pacific Biosciences (PACB), +16% Wed — Rose with a broader move in AI-biological-data-generation names; separately, the US government banned imports from BGI Genomics, a Chinese NGS maker. PACB makes long-read sequencing instruments and open-source bioinformatics software.
- Schrodinger (SDGR), +15% Wed — No company-specific news; computational-chemistry/molecular-modeling platform.
- Beam Therapeutics (BEAM), +15% Wed — Rose on promising Phase 1/2 data for BEAM-301 in Glycogen Storage Disease 1a (elimination of starch supplementation, no serious adverse events). Beam develops base-editing therapeutics.
- Roblox (RBLX), -17% Fri — Fell on Q3 earnings: DAUs missed and management guided Q4 bookings down 10-15% YoY. Roblox is a creator-first gaming/3D-engine platform.
- CareDx (CDNA), +22% Fri — Rose on a Q3 beat (testing volume, pricing, NavDx contribution) plus raised full-year guidance. CareDx is a molecular-diagnostics company for transplant and oncology patients.
- Illumina (ILMN), -18% Fri — Fell on Q3 earnings: 5% organic revenue growth (14% in clinical sequencing consumables) came in below the 2027 high-single-digit growth target. Illumina makes genetic-analysis systems.
- Quantum-Si (QSI), -17% Fri — No company-specific news, "difficult market" framing. Protein-sequencing instrument maker (proprietary time-domain sequencing).
- Bullish (BLSH), -16% Fri — Fell after Binance disclosed a ~$6.3B hack (attacker compromised a DevOps engineer's laptop to forge withdrawal signatures across ten blockchains in ~20 minutes); BTC/ETH each fell >3% on broad custody/counterparty reassessment. Bullish is a blockchain exchange that owns CoinDesk and its indexes.
Mapping against Ray Data Co
The load-bearing item is the QSI pattern, not any single stock pick: this is the fourth consecutive weekly ARK commentary logging a QSI move "on no company-specific news" — [[2026-10-03-ark-invest-stock-commentary-qsi-pacb-sctx]], [[2026-10-10-ark-invest-stock-commentary-qsi-rxrx-twst-txg-almr-pacb]], and [[2026-10-23-ark-invest-stock-commentary-iam-qsi-wgs]] all show the same framing. Four straight weeks of a thinly-traded name moving double digits with zero stated catalyst is itself a data point for [[project_investing_markov_capital_cycle]]'s thesis-testing: it's a reminder that ARK's own stock-specific narration is frequently post-hoc noise-labeling rather than signal, which argues for weighting ARK commentary low as an input, not high. PACB breaks that pattern this week with an actual catalyst (the BGI Genomics import ban) — a concrete China-decoupling data point in the sequencing-hardware supply chain, worth a one-line flag for any future AI-bio-data capital-cycle write-up, but founder guidance (2026-10-05, [[project_ambition_bigger_problem_network]]) already dropped HCLS/biotech as his space, so it doesn't change current priorities. BLSH/Binance is a live custody-risk headline but has no RDCO-specific hook beyond general "centralized-exchange security is fragile" color. The rest (NU, PRME, SDGR, BEAM, RBLX, CDNA, ILMN) are earnings/macro moves with zero connection to phData, Scribble Works, or RDCO's agent-capability thesis.
Mapping is weak — one recurring pattern worth tracking (QSI no-news moves) and one tangential supply-chain data point (PACB/BGI), nothing touching RDCO's actual product or technical surface. Filing honestly as weak rather than forcing a stronger claim.
Related
- [[2026-10-23-ark-invest-stock-commentary-iam-qsi-wgs]]
- [[2026-10-10-ark-invest-stock-commentary-qsi-rxrx-twst-txg-almr-pacb]]
- [[2026-10-03-ark-invest-stock-commentary-qsi-pacb-sctx]]
- [[project_investing_markov_capital_cycle]]